Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing

Area of Science:

• Genetics
• Molecular Diagnostics
• Bioinformatics

Background:

• High-throughput sequencing methods are crucial for molecular diagnostics.
• Next-generation sequencing (NGS) is increasingly adopted for genetic analysis.
• Accurate detection of BRCA1 and BRCA2 mutations is vital for hereditary cancer risk assessment.

Purpose of the Study:

• To develop and validate a workflow for detecting BRCA1 and BRCA2 mutations using massive parallel sequencing.
• To assess the sensitivity and specificity of this NGS approach for clinical diagnosis.
• To evaluate the potential of massive parallel pyrosequencing as a replacement for traditional Sanger sequencing.

Main Methods:

• Utilized the 454 GS Junior benchtop sequencer for massive parallel sequencing.
• Employed the BRCA MASTR kit for Polymerase Chain Reaction (PCR) amplification and enrichment of BRCA1 and BRCA2 exons.
• Analyzed sequencing reads using AVA software v2.7 and addressed homopolymer-related false positives with the BRCA HP kit.

Main Results:

• Achieved 100% sensitivity in detecting 62 known variants in an initial validation panel.
• Initial specificity was 97.35%, with false positives primarily linked to homopolymer stretches.
• Implementing the BRCA HP kit for homopolymer analysis improved specificity to 99.99%.

Conclusions:

• Massive parallel pyrosequencing provides a highly sensitive and specific method for BRCA1 and BRCA2 mutation detection.
• The developed workflow meets stringent diagnostic parameters, offering a cost-effective and efficient alternative to Sanger sequencing.
• This NGS strategy is suitable for diagnosing patients with familial breast and ovarian cancer.